Current practices in laboratory monitoring of HIV infection

After a diagnosis of HIV infection is made, the patient needs to be monitored using both clinical assessment and laboratory markers. HIV/AIDS monitoring is essential in guiding when to recommend initiation of therapy. Clinical monitoring will include staging of the HIV/AIDS disease using either the presence or absence of HIV-related signs and symptoms using the WHO staging system. Various laboratory methods can be used to monitor the disease progression and to guide whether the patient will need antiretroviral therapy or not. Laboratory monitoring for patients who are not on drugs is done to provide information about the stage of illness; to enable the clinician to make decisions on treatment and to give information on prognosis of the patient. Patients on drugs are monitored to assess their response to treatment with antiretroviral drugs and to detect any possible toxicity and improvement associated with the antiretroviral drugs.

[1]  W. Göhde,et al.  Affordable CD4+ T‐cell counts on ‘single‐platform’ flow cytometers I. Primary CD4 gating , 2000, British journal of haematology.

[2]  T. Quinn,et al.  A manual bead assay for the determination of absolute CD4+ and CD8+ lymphocyte counts in human immunodeficiency virus-infected individuals , 1995, Clinical and diagnostic laboratory immunology.

[3]  J M Taylor,et al.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. , 1990, The New England journal of medicine.

[4]  M. Bergeron,et al.  Evolution of leukocyte immunophenotyping as influenced by the HIV/AIDS pandemic: a short history of the development of gating strategies for CD4+ T-cell enumeration. , 1997, Cytometry.

[5]  R. Badaró,et al.  Performance of the automated Abbott RealTime HIV-1 assay on a genetically diverse panel of specimens from Brazil. , 2006, Journal of virological methods.

[6]  N. Ford,et al.  HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Covas,et al.  Hematological abnormalities in HIV-infected patients. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[8]  J. Michalek,et al.  Immunological parameters in current and former US Air Force personnel. , 1993, Vaccine.

[9]  I. Sanne,et al.  Cost-Effectiveness of Alternative Strategies for Initiating and Monitoring Highly Active Antiretroviral Therapy in the Developing World , 2007, Journal of acquired immune deficiency syndromes.

[10]  R. Steigbigel,et al.  A comparison of the Coulter STKS, Coulter S+IV, and manual analysis of white blood cell differential counts in a human immunodeficiency virus-infected population. , 1993, American journal of clinical pathology.

[11]  M. Peeters,et al.  New and old complex recombinant HIV-1 strains among patients with primary infection in 1996–2006 in France: The French ANRS CO06 primo cohort study , 2008, Retrovirology.

[12]  D. Ho,et al.  Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy , 1999, Journal of Virology.

[13]  L. Scott,et al.  Fluorogenic LUX primer for quantitation of HIV-1 by real-time RT-PCR , 2006, Molecular biotechnology.

[14]  B. Autran,et al.  Consistency of routine measurements of CD4+, CD8+ peripheral blood lymphocytes. , 1992, Journal of immunological methods.

[15]  Milton C Weinstein,et al.  Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. , 2006, The New England journal of medicine.

[16]  G. Pan,et al.  Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. , 2005, Journal of virological methods.

[17]  Bruno Ledergerber,et al.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.

[18]  R. Pandey,et al.  Lymphocyte immunophenotype reference ranges in healthy Indian adults: implications for management of HIV/AIDS in India. , 2004, Clinical immunology.

[19]  C. Tinelli,et al.  Predictors of Long-Term Immunological Outcome in Rebounding Patients on Protease Inhibitor-Based HAART After Initial Successful Virologic Suppression: Implications for Timing to Switch , 2003, HIV clinical trials.

[20]  Richard A. Loftus,et al.  Global cost modeling analysis of HIV-1 and HCV viral load assays , 2003, Expert review of pharmacoeconomics & outcomes research.

[21]  D. Katzenstein,et al.  Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. , 2008, Archives of internal medicine.

[22]  G. N. Bazuaye,et al.  Autoimmune hemolytic anemia in HIV-infected patients: a hospital based study. , 2008, Annals of African medicine.

[23]  Á. Holguín,et al.  Comparison of Three Different Commercial Methods for Measuring Plasma Viraemia in Patients Infected with Non-B HIV-1 Subtypes , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[24]  J. Giorgi Characterization of T Lymphocyte Subset Alterations by Flow Cytometry in HIV Disease , 1993, Annals of the New York Academy of Sciences.

[25]  A. Breckenridge,et al.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. , 2010, Lancet.

[26]  T. Flanigan,et al.  Natural history of human immunodeficiency virus disease in southern India. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  F. Hecht,et al.  Quantitative and Cost Comparison of Ultrasensitive Human Immunodeficiency Virus Type 1 RNA Viral Load Assays: Bayer bDNA Quantiplex Versions 3.0 and 2.0 and Roche PCR Amplicor Monitor Version 1.5 , 2000, Journal of Clinical Microbiology.

[28]  F. González-Sastre,et al.  The Predictive Value of Several Markers in the Progression to Acquired Immunodeficiency Syndrome , 1998, Clinical chemistry and laboratory medicine.

[29]  H. Günthard,et al.  HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. , 2003, Journal of acquired immune deficiency syndromes.

[30]  J. Braun,et al.  A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes , 2003, AIDS.

[31]  J. Malone,et al.  Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. , 1990, Journal of acquired immune deficiency syndromes.

[32]  F. Brun-Vézinet,et al.  Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of clinical microbiology.

[33]  J. Vincelette,et al.  Multicenter Comparison of Roche COBAS AMPLICOR MONITOR Version 1.5, Organon Teknika NucliSens QT with Extractor, and Bayer Quantiplex Version 3.0 for Quantification of Human Immunodeficiency Virus Type 1 RNA in Plasma , 2000, Journal of Clinical Microbiology.

[34]  Alimuddin Zumla,et al.  Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients , 2003, The Lancet.

[35]  F. Hecht,et al.  The Relation Between Symptoms, Viral Load, and Viral Load Set Point in Primary HIV Infection , 2007, Journal of acquired immune deficiency syndromes.

[36]  Lesley E Scott,et al.  CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration. , 2002, Cytometry.

[37]  W. Blattner,et al.  The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers , 1989, Journal of Clinical Immunology.

[38]  L. Scott,et al.  Evaluation of the NucliSens EasyQ assay in HIV-1-infected individuals in South Africa. , 2005, Journal of virological methods.

[39]  J. Temple,et al.  Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. , 2004, Journal of virological methods.

[40]  A. Phillips,et al.  Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. , 1996, Genitourinary medicine.

[41]  L. Ferradini,et al.  Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. , 2004, AIDS.

[42]  D. K. Benjamin,et al.  Rational testing of the HIV-exposed infant. , 2001, Pediatrics.

[43]  B. Poiesz,et al.  Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants. , 1999, The Pediatric infectious disease journal.

[44]  J. Nicholson,et al.  Evaluation of alternative CD4 technologies for the enumeration of CD4 lymphocytes. , 1994, Journal of immunological methods.

[45]  Cathy A Petti,et al.  Laboratory medicine in Africa: a barrier to effective health care. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  R. Paranjape,et al.  Relationship between clinical conditions and CD4 counts in HIV-infected persons in Pune, Maharashtra, India. , 2000, The National medical journal of India.

[47]  S. Hammer,et al.  The challenge of HIV-1 subtype diversity. , 2008, The New England journal of medicine.

[48]  L. Bacheler,et al.  HIV drug resistance tests: an update on methods for calculating phenotypic fold change from a viral genotype. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  F. Simon,et al.  Plasma RNA viral load in HIV-1 group O infection by real-time PCR. , 2005, Methods in molecular biology.

[50]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[51]  J. Nicholson,et al.  CD4 T-lymphocyte determinations on whole blood specimens using a single-tube three-color assay. , 1993, Cytometry.

[52]  C. Rouzioux,et al.  HIV-1 viral load testing cost in developing countries: what’s new? , 2007, Expert review of molecular diagnostics.

[53]  V. Sreenivas,et al.  Correlation of immune activation with HIV-1 RNA levels assayed by real-time RT-PCR in HIV-1 subtype C infected patients in Northern India. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[54]  James Bethel,et al.  Performance Characteristics of HIV-1 Culture and HIV-1 DNA and RNA Amplification Assays for Early Diagnosis of Perinatal HIV-1 Infection , 2003, Journal of acquired immune deficiency syndromes.

[55]  P. Volberding,et al.  Human immunodeficiency virus hematology. , 2003, Hematology. American Society of Hematology. Education Program.

[56]  M. Giacomini,et al.  A novel and innovative quantitative kinetic software for virological colorimetric assays. , 1998, Journal of virological methods.

[57]  R. Gelman,et al.  Analyses of quality assessment studies using CD45 for gating lymphocytes for CD3(+)4(+)%. , 2000, Cytometry.

[58]  H. Nagaraja,et al.  Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. , 1998, American journal of respiratory and critical care medicine.

[59]  T. Leitner,et al.  HIV‐1 viral load determination based on reverse transcriptase activity recovered from human plasma , 2003, Journal of medical virology.

[60]  R. Écochard,et al.  HIV-1 Load Comparison Using Four Commercial Real-Time Assays , 2010, Journal of Clinical Microbiology.

[61]  S. Kleinman,et al.  Soluble IL-2 receptor levels in serum from blood donors seropositive for HIV. , 1988, Journal of immunology.

[62]  T. Schaberg,et al.  Lymphocyte Subsets in Peripheral Blood and Smoking Habits , 1997, Lung.

[63]  C. Sabin,et al.  Serum beta 2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[64]  F. Goebel,et al.  Serum neopterin levels as predictor of AIDS , 1988, Klinische Wochenschrift.

[65]  S. Cantor,et al.  Cost - Effectiveness Analysis, Extended Dominance, and Ethics , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[66]  Claire DeCristofaro,et al.  Anal Pap smears: Should we be doing them? , 2009, Journal of the American Academy of Nurse Practitioners.

[67]  M. Aboud,et al.  Clinical Utility of Genotypic Resistance Tests for HIV-1-Infected Patients with Low-Level Virological Failure , 2010, Journal of Clinical Microbiology.

[68]  W. Owiredu,et al.  Prevalence of anaemia and immunological markers among ghanaian HAART-naïve HIV-patients and those on HAART. , 2011, African health sciences.

[69]  M. Hirsch,et al.  Monitoring HIV treatment in developing countries , 2006, BMJ : British Medical Journal.

[70]  M. Choong,et al.  Influence of Race, Age and Sex on the Lymphocyte Subsets in Peripheral Blood of Healthy Malaysian Adults , 1995, Annals of clinical biochemistry.

[71]  T. Leitner,et al.  Improved HIV‐1 viral load determination based on reverse transcriptase activity recovered from human plasma , 2005, Journal of medical virology.

[72]  F. Chew,et al.  Age- and sex-related changes in lymphocyte subpopulations of healthy Asian subjects: from birth to adulthood. , 1996, Cytometry.

[73]  D. Fuchs,et al.  An evaluation of low‐cost progression markers in HIV‐1 seropositive Zambians , 2000, HIV medicine.

[74]  T. Flanigan,et al.  Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[75]  George Janossy,et al.  Affordable CD4(+) T-cell counts on 'single-platform' flow cytometers I. Primary CD4 gating. , 2000 .

[76]  D. Burke,et al.  Department of Army lymphocyte immunophenotyping quality assurance program. , 1989, Clinical immunology and immunopathology.

[77]  D. Wolday,et al.  Reverse transcriptase activity for quantitation of HIV‐1 subtype C in plasma: Relation to RNA copy number and CD4 T‐cell count , 2006, Journal of medical virology.

[78]  H. Klinker,et al.  The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection , 2011, Therapeutic drug monitoring.

[79]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[80]  T. Sudarsanam,et al.  Evidence for lower CD4+ T cell and higher viral load in asymptomatic HIV-1 infected individuals of India: implications for therapy initiation. , 2008, Indian journal of medical microbiology.

[81]  P. Roques,et al.  Plasma viral RNA assay in HIV-1 group O infection by real-time PCR. , 2003, Journal of virological methods.

[82]  M R Loken,et al.  Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. , 1990, Cytometry.

[83]  V. Soriano,et al.  Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT , 2005, Journal of Clinical Microbiology.

[84]  E. Acosta,et al.  Therapeutic drug monitoring in the treatment of HIV-infection. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[85]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[86]  R. Miller,et al.  The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. , 1985, Cytometry.

[87]  K. Anastos,et al.  Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. , 2003, Journal of the National Cancer Institute.

[88]  M. Jesudason,et al.  Correlation of CD4+ T-Cell Counts Estimated by an Immunocapture Technique (Capcellia) with Viral Loads in Human Immunodeficiency Virus-Seropositive Individuals , 2001, Clinical Diagnostic Laboratory Immunology.

[89]  D. Kyle,et al.  Flow cytometric immunophenotyping of lymphocyte subsets in samples that contain a high proportion of non-lymphoid cells. , 1994, Cytometry.

[90]  A. Badley,et al.  Selection of lymphocyte gating protocol has an impact on the level of reliability of T-cell subsets in aging specimens. , 2002, Cytometry.

[91]  Jaap Goudsmit,et al.  One-Tube Real-Time Isothermal Amplification Assay To Identify and Distinguish Human Immunodeficiency Virus Type 1 Subtypes A, B, and C and Circulating Recombinant Forms AE and AG , 2001, Journal of Clinical Microbiology.

[92]  Michael S Saag,et al.  Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[93]  D. Quaglino,et al.  Changes in the expression of surface receptors on lymphocyte subsets in the elderly: Quantitative flow cytometric analysis , 2001, American journal of hematology.

[94]  R. Walensky,et al.  Scaling Up the 2010 World Health Organization HIV Treatment Guidelines in Resource-Limited Settings: A Model-Based Analysis , 2010, PLoS medicine.

[95]  A. P. D. Ponce de Leon,et al.  Surrogate markers of disease progression in HIV-infected children in Rio de Janeiro, Brazil. , 1999, Journal of tropical pediatrics.

[96]  V. Sreenivas,et al.  CDC staging based on absolute CD4 count and CD4 percentage in an HIV‐1‐infected Indian population: treatment implications , 2005, Clinical and experimental immunology.

[97]  M. Majchrowicz Beyond antiretroviral access: low-cost laboratory tests needed for the developing world. , 2003, AIDS.

[98]  Robert Oelrichs,et al.  Monitoring of human immunodeficiency virus infection in resource-constrained countries. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[99]  R. Greenblatt,et al.  Does patient sex affect human immunodeficiency virus levels? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  W. S. Clark,et al.  Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.

[101]  P. Ghys,et al.  Comparison of NucliSens and Amplicor Monitor Assays for Quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Plasma of Persons with HIV-1 Subtype A Infection in Abidjan, Côte d’Ivoire , 1998, Journal of Clinical Microbiology.

[102]  David Bishai,et al.  The cost effectiveness of antiretroviral treatment strategies in resource-limited settings , 2007, AIDS.

[103]  Deenan Pillay,et al.  Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model , 2008, The Lancet.

[104]  K. Mayer,et al.  Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. , 2005, The Indian journal of medical research.

[105]  D. Torre,et al.  Platelets and HIV-1 infection: old and new aspects. , 2008, Current HIV research.

[106]  J. Moskowitz,et al.  Pediatric HIV Costs Across Three Treatment Eras From 1986 to 2007 , 2010, Pediatrics.

[107]  J. Hocking,et al.  Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. , 2005, Current HIV research.

[108]  Xavier Anglaret,et al.  Transfer and Evaluation of an Automated, Low-Cost Real-Time Reverse Transcription-PCR Test for Diagnosis and Monitoring of Human Immunodeficiency Virus Type 1 Infection in a West African Resource-Limited Setting , 2005, Journal of Clinical Microbiology.

[109]  J. Fahey,et al.  Distinct categories of immunologic changes in frail elderly , 2000, Mechanisms of Ageing and Development.

[110]  C. Gilks,et al.  Cost Effectiveness Analysis of Routine Laboratory or Clinically Driven Strategies for Monitoring Anti-Retroviral Therapy in Uganda and Zimbabwe (DART Trial) , 2009 .

[111]  Christopher D. Pilcher,et al.  Comparison of NucliSens and Roche Monitor Assays for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1999, Journal of Clinical Microbiology.

[112]  Lesley Scott,et al.  Performance of the New Roche Cobas AmpliPrep-Cobas TaqMan Version 2.0 Human Immunodeficiency Virus Type 1 Assay , 2009, Journal of Clinical Microbiology.

[113]  R. Holzman,et al.  Human Immunodeficiency Virus (HIV) Reverse Transcriptase Activity Correlates with HIV RNA Load: Implications for Resource-Limited Settings , 2005, Journal of Clinical Microbiology.

[114]  M. Kalish,et al.  Sensitivity and specificity of a qualitative RNA detection assay to diagnose HIV infection in young infants. Perinatal AIDS Collaborative Transmission Study. , 1998, AIDS.

[115]  N. Shaffer,et al.  Early Diagnosis of HIV‐1‐Infected Infants in Thailand Using RNA and DNA PCR Assays Sensitive to Non‐B Subtypes , 2000, Journal of acquired immune deficiency syndromes.

[116]  F. Heinz,et al.  Comparison of virtual phenotype and HIV‐SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains , 2002, HIV medicine.

[117]  T. Wrin,et al.  CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. , 2002, The Journal of infectious diseases.

[118]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[119]  G. Cordero [HIV infection]. , 1995, SIDAhora : un proyecto del Departamento de Publicaciones del PWA Coalition, NY.

[120]  Kenneth H Mayer,et al.  An Inexpensive, Simple, and Manual Method of CD4 T-Cell Quantitation in HIV-Infected Individuals for Use in Developing Countries , 2004, Journal of acquired immune deficiency syndromes.

[121]  J M Taylor,et al.  CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. , 1989, Journal of acquired immune deficiency syndromes.

[122]  F. Samuels,et al.  Population mobility and HIV and AIDS: review of laws, policies and treaties between Bangladesh, Nepal and India , 2011 .

[123]  Lei Wang,et al.  Association of HIV Diversity and Survival in HIV-Infected Ugandan Infants , 2011, PloS one.

[124]  D. Costagliola,et al.  Modeling the Time Course of CD4 T-Lymphocyte Counts According to the Level of Virologic Rebound in HIV-1–Infected Patients on Highly Active Antiretroviral Therapy , 2003, Journal of acquired immune deficiency syndromes.

[125]  S S Uppal,et al.  Normal values of CD4 and CD8 lymphocyte subsets in healthy indian adults and the effects of sex, age, ethnicity, and smoking , 2003, Cytometry. Part B, Clinical cytometry.